GeoVax Labs (GOVX) Set to Announce Earnings on Tuesday

GeoVax Labs (NASDAQ:GOVX) will be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Tuesday, August 6th. The company reported ($1.99) EPS for the quarter, topping the consensus estimate of ($2.57) by $0.58. The business had revenue of $0.30 million for the quarter. During the same quarter in the previous year, the company earned ($3.30) earnings per share. On average, analysts expect GeoVax Labs to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GeoVax Labs Trading Down 0.7 %

Shares of GOVX stock opened at $1.81 on Wednesday. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The stock has a 50 day simple moving average of $2.76 and a 200 day simple moving average of $2.56.

Analysts Set New Price Targets

GOVX has been the subject of a number of analyst reports. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Monday, August 12th. Noble Financial lifted their target price on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, August 19th. Finally, Roth Mkm initiated coverage on shares of GeoVax Labs in a report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price target on the stock. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GeoVax Labs currently has an average rating of “Buy” and a consensus target price of $12.67.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.